Article info

Download PDFPDF

495 BYON4228, a pan-allelic SIRPα blocking antibody with a favorable pre-clinical safety profile, enhances anti-tumor immunity in vitro and in vivo
Free

Authors

Citation

Helden MV, Arends R, Zwarthoff S, et al
495 BYON4228, a pan-allelic SIRPα blocking antibody with a favorable pre-clinical safety profile, enhances anti-tumor immunity in vitro and in vivo

Publication history

  • First published November 7, 2022.
Online issue publication 
November 07, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.